Dietary calcium supplementation enhances efficacy but also toxicity of EGFR inhibitor therapy for colon cancer

被引:5
|
作者
Rinella, Erica S. [1 ,2 ]
Bankaitis, Eric D. [1 ,2 ]
Threadgill, David W. [1 ,2 ,3 ]
机构
[1] Univ N Carolina, Dept Genet Curriculum Genet & Mol Biol, Lineberger Canc Ctr, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC USA
[3] N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA
基金
美国国家卫生研究院;
关键词
colon cancer; EGFR; calcium; mouse models; AG1478; therapy; toxicity; GROWTH-FACTOR RECEPTOR; SENSING RECEPTOR; ADENOMAS; HYPERPROLIFERATION; CARCINOGENESIS; CARCINOMAS; EXPRESSION; PREVENTION; MODEL;
D O I
10.4161/cbt.13.3.18690
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The inverse correlation between levels of dietary calcium and colorectal cancer (CRC) incidence has been extensively investigated. However, the impact of supplemental calcium on cancer therapy remains unknown. We used four models of CRC, Caco-2 and HCT116 human cancer cell lines and Apc(Min/+) and azoxymethane carcinogen-induced mouse models, to investigate the impact of a western-style diet low in calcium (0.05%) vs. a similar diet but supplemented with calcium (5%) on therapeutic targeting of the epidermal growth factor receptor (EGFR). We found that calcium supplementation combined with pharmacologic blockade of EGFR results in an additive effect on tumor growth inhibition in all models. Unexpectedly, the combined use of dietary calcium supplementation and EGFR inhibitors also resulted in elevated toxicity suggesting that careful consideration be given when combining dietary supplements with prescribed cancer therapies.
引用
收藏
页码:130 / 137
页数:8
相关论文
共 50 条
  • [41] Inhibition of EZH2/EZH1 by UNC1999 Enhances the Potency of the EGFR Inhibitor Gefitinib in Colon Cancer Cells
    Katona, Bryson
    Liu, Yuanyuan
    Ma, Anqi
    Jin, Jian
    Hua, Xianxin
    GASTROENTEROLOGY, 2014, 146 (05) : S626 - S626
  • [42] Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells
    A Di Paolo
    R Danesi
    S Caputo
    M Macchia
    M Lastella
    U Boggi
    F Mosca
    A Marchetti
    M Del Tacca
    British Journal of Cancer, 2001, 84 : 1535 - 1543
  • [43] COMBINED THERAPY WITH NEXT GENERATION EGFR INHIBITOR AND MET KINASE INHIBITOR FOR OVERCOMING THE RESISTANCE IN EGFR MUTANT LUNG CANCER
    Nanjo, Shigeki
    Yamada, Tadaaki
    Nakagawa, Takayuki
    Takeuchi, Shinji
    Mitsudomi, Tetsuya
    Yano, Seiji
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S453 - S453
  • [44] EFFICACY AND TOXICITY OF 5-FLUOROURACIL AND FOLATES IN ADVANCED COLON CANCER
    CORTESI, E
    ASCHELTER, AM
    GIOACCHINI, N
    PELLEGRINI, A
    FRATI, L
    FICORELLA, C
    MAZZEI, N
    MARCHETTI, P
    JOURNAL OF CHEMOTHERAPY, 1990, 2 : 47 - 50
  • [45] Calcium daily intake and the efficacy of a training intervention on optimizing calcium supplementation therapy: A clinical audit
    Muscariello, Riccardo
    Rendina, Domenico
    Giannettino, Raffaele
    Ippolito, Serena
    Romano, Ornella
    Coretti, Federica
    De Vita, Simone
    Martino, Mariarosaria
    Sepe, Carolina
    Nuzzo, Vincenzo
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2021, 31 (01) : 354 - 360
  • [46] Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
    Wong, Selina K.
    Nebhan, Caroline A.
    Johnson, Douglas B.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [47] Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells
    Liang, Kang-Hao
    Tso, Hsien-Cheng
    Hung, Shao-Hsi
    Kuan, I. -I.
    Lai, Jun-Kai
    Ke, Feng-Yi
    Chuang, Yi-Ting
    Liu, I-Ju
    Wang, Yi-Ping
    Chen, Ruey-Hwa
    Wu, Han-Chung
    CANCER LETTERS, 2018, 433 : 165 - 175
  • [48] Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
    Zhao, Jun
    Lee, Patrick
    Wallace, Michael J.
    Melancon, Marites P.
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (29) : 4240 - 4251
  • [49] Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
    Lacouture, Mario E.
    Anadkat, Milan
    Jatoi, Aminah
    Garawin, Tamer
    Bohac, Chet
    Mitchell, Edith
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : 85 - 96
  • [50] KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
    Siddiqui, Ahmad D.
    Piperdi, Bilal
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (04) : 1168 - 1176